Offline
| Post a Message | Explore Forums | Browse Stock Messages | Hot Discussions | Top rated Messages | Top Boarders | |
|
|
|
Biocon
Biocon Hold from BL
Posted by :
psgsTracked by: 1 Boarder
hi sanecouncelji,
what is the bad news?
swamy.
...
In reply to:
Biocon Hold from BL
Posted by :
sanecouncel.
stock is up on bad news, then becho naa, only sell sell and sell, golden rule of trading price goes below 400 only buy , price goes up only sell......cheers saveraji you must have booked profit also. 
Biocon approves bonus share in 1:1
Posted by : shenoyTracked by: 0 Boarder
Bangalore-based Biotech major, Biocon Limited has informed that the members at the Annual General Meeting of the Company has finally approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company.
Further the company has announced that the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members.
Last month, Biocon launched the drug Abraxane in India as a single use 100 mg vial, which is used in the treatment of breast cancer.
The company for the first time has reported a 72% decline in net profit at Rs 15 crore for the first-quarter (Q1) ended June 30, 2008 as compared to Rs 53 crore reported in the corresponding quarter of last year.
The stock has corrected over 35 per cent in 2008, under-performing the broader indices and now trades at Rs 405, up 5% compared to its previous close. Traders with short-term perspective can buy the stock with a price target of 440, while maintaining stop-loss at Rs 390....
Biocon fixes Record Date for Bonus Issue
Posted by : shenoyTracked by: 0 Boarder
: Biocon Ltd has informed BSE that the members at the Annual General Meeting of the Company held on July 18, 2008 approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company.
Further to the same, the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members....
Biocon Hold from BL
Posted by : sanecouncel.Tracked by: 1 Boarder
stock is up on bad news, then becho naa, only sell sell and sell, golden rule of trading price goes below 400 only buy , price goes up only sell......cheers saveraji you must have booked profit also....
In reply to:
Biocon Hold from BL
Posted by : psgs
howcome, the date has been postponed from 18th august to 12 september 2008 for bonus issue. and the stock was up by 5% today. why? any reason?
swamy.
oral insulin enters latestage trials
Posted by : sanecouncel.Tracked by: 0 Boarder
hi pgps bhai, this is called in 105, i was expecting this kind of news only after bonus in sept but it came a bit early, so what about those who sold in eye qwash-result day at 370, should they buy again for now on this news , i dont think so... what is your view
till then sing \\\\...
In reply to:
oral insulin enters latestage trials
Posted by : shenoy
Biocons oral insulin alternative enters late-stage trials
The company, which will present the phase IIa trial data of its new molecule IN 105 at the European Association for the Study of Diabetes meeting in Rome in September, says that for the first time, oral insulin has shown good dose linearity.
Bangalore: Biocon Ltds oral insulin, which aims to be a needleless alternative to the injection, has advanced to late-stage trials, having shown promising results in the mid-stage studies in India.
The company, which will present the phase IIa trial data (phase IIa typically measures dosage requirements) of its new molecule IN 105 at the European Association for the Study of Diabetes meeting in Rome in September, says that for the first time, oral insulin has shown good dose linearity. Dose linearity essentially means the response of the drug is proportional to the units consumed, an important parameter in its predictability.
This study clearly demonstrated a near-perfect linear dose response, which is most encouraging, says Kiran Mazumdar-Shaw, chairman and managing director of Biocon. Additionally, a significant two-hour post-prandial glucose drop has been seen, which indicates that IN105 has potential in demonstrating efficacy in longer-term trials, she added.
However, what will really determine its clinical efficacy is the next study that will have HbA1c (a measure of blood sugar control over three months) as the end point, says Harish Iyer, head (research and development) at Biocon. The company has conducted four studies so far and is now readying for a large, three-six-month study.
This will tell us the real positioning of IN105 as an early insulin intervention for patients with early onset of diabetes, says Mazumdar-Shaw. Obviously this will mean a new therapeutic paradigm for diabetes that has enormous business prospects for Biocon. The drug is expected to be launched in 2010.
Initially targeted at type II diabetes, where at least 30% people need some sort of insulin, IN105 is packaged as a tablet using a proprietary polymer technology, acquired by Biocon from US firm Nobex Corp., which allows modification in the drug structure for oral delivery. Biocon later bought all IP assets of Nobex when it filed for bankruptcy in 2005.
It seems a promising therapy, but I’d look for data from large-scale studies and extended post-marketing surveillance, says Anoop Misra, director (department of diabetes and metabolic diseases) at Fortis Healthcare Rajan Dhall Hospital, New Delhi. Citing the example of the popular diabetes drug rosiglitazone (brand name: Avandia), he says the drug showed side effects almost seven years after its launch and led US Food and Drug Administration to issue safety warnings.
Even Pfizer Inc.’s inhaled insulin Exubera, whose sales were halted in October, barely a year after its launch, started reporting cases of lung cancer after it hit the market. Even though we know a lot about insulin, the fact that it is being given through a new route warrants strict surveillance, cautions Dr Misra.
Biocon, which also makes regular insulin, is aware of the challenges ahead, but is counting on the drug for several reasons. Insulin, says Iyer, has some serious issues, which IN105 manages to get around. It ensures better patient compliance, as it isn’t an injection. Further, insulin is deposited under the skin and leads to weight gain, which is a risk factor for other disorders. With oral insulin, we think, it’ll be either weight-neutral, or weight loss, he says.
Finally, because insulin lies in a sort of subcutaneous depot, it acts over a long time and causes hypoglycemia (lower than normal level of glucose) if there’s any slight change in diet, or the insulin intake. IN105, on the other hand, is a rapid acting drug and staves off the risk of hypoglycemia, argues Iyer.
Big Pharma, with its niche in the conventional small molecule drug, hasn’t fancied the biotechnology route for diabetes. The only oral insulin close to the market, according to Dr Misra, is a spray called Oralyn, developed by the Toronto, Canada-based Generex Biotechnology Corp., which has a marketing agreement for India with Shreya Life Sciences Pvt. Ltd, Mumbai.
Biocon Hold from BL
Posted by : psgsTracked by: 1 Boarder
howcome, the date has been postponed from 18th august to 12 september 2008 for bonus issue. and the stock was up by 5% today. why? any reason?
swamy.
...
In reply to:
Biocon Hold from BL
Posted by : sanecouncel.
other reason is , many small investors fear to buy shares quoting above 200 and after bonus biocon price will came with in their sentimental range and they will start buying and share price cwill fall for sure
NSE Announcements on Biocon
Posted by : MMB MessengerTracked by: 0 Boarder
Biocon Limited has informed the Exchange that the members at the Annual General Meeting of the Company held on July 18, 2008 approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company. Further to the same, the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members....
BSE Announcements on Biocon
Posted by : MMB MessengerTracked by: 0 Boarder
Biocon Ltd has informed BSE that the members at the Annual General Meeting of the Company held on July 18, 2008 approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company.
Further to the same, the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members....
oral insulin enters latestage trials
Posted by : shenoyTracked by: 0 Boarder
Biocons oral insulin alternative enters late-stage trials
The company, which will present the phase IIa trial data of its new molecule IN 105 at the European Association for the Study of Diabetes meeting in Rome in September, says that for the first time, oral insulin has shown good dose linearity.
Bangalore: Biocon Ltds oral insulin, which aims to be a needleless alternative to the injection, has advanced to late-stage trials, having shown promising results in the mid-stage studies in India.
The company, which will present the phase IIa trial data (phase IIa typically measures dosage requirements) of its new molecule IN 105 at the European Association for the Study of Diabetes meeting in Rome in September, says that for the first time, oral insulin has shown good dose linearity. Dose linearity essentially means the response of the drug is proportional to the units consumed, an important parameter in its predictability.
This study clearly demonstrated a near-perfect linear dose response, which is most encouraging, says Kiran Mazumdar-Shaw, chairman and managing director of Biocon. Additionally, a significant two-hour post-prandial glucose drop has been seen, which indicates that IN105 has potential in demonstrating efficacy in longer-term trials, she added.
However, what will really determine its clinical efficacy is the next study that will have HbA1c (a measure of blood sugar control over three months) as the end point, says Harish Iyer, head (research and development) at Biocon. The company has conducted four studies so far and is now readying for a large, three-six-month study.
This will tell us the real positioning of IN105 as an early insulin intervention for patients with early onset of diabetes, says Mazumdar-Shaw. Obviously this will mean a new therapeutic paradigm for diabetes that has enormous business prospects for Biocon. The drug is expected to be launched in 2010.
Initially targeted at type II diabetes, where at least 30% people need some sort of insulin, IN105 is packaged as a tablet using a proprietary polymer technology, acquired by Biocon from US firm Nobex Corp., which allows modification in the drug structure for oral delivery. Biocon later bought all IP assets of Nobex when it filed for bankruptcy in 2005.
It seems a promising therapy, but I’d look for data from large-scale studies and extended post-marketing surveillance, says Anoop Misra, director (department of diabetes and metabolic diseases) at Fortis Healthcare Rajan Dhall Hospital, New Delhi. Citing the example of the popular diabetes drug rosiglitazone (brand name: Avandia), he says the drug showed side effects almost seven years after its launch and led US Food and Drug Administration to issue safety warnings.
Even Pfizer Inc.’s inhaled insulin Exubera, whose sales were halted in October, barely a year after its launch, started reporting cases of lung cancer after it hit the market. Even though we know a lot about insulin, the fact that it is being given through a new route warrants strict surveillance, cautions Dr Misra.
Biocon, which also makes regular insulin, is aware of the challenges ahead, but is counting on the drug for several reasons. Insulin, says Iyer, has some serious issues, which IN105 manages to get around. It ensures better patient compliance, as it isn’t an injection. Further, insulin is deposited under the skin and leads to weight gain, which is a risk factor for other disorders. With oral insulin, we think, it’ll be either weight-neutral, or weight loss, he says.
Finally, because insulin lies in a sort of subcutaneous depot, it acts over a long time and causes hypoglycemia (lower than normal level of glucose) if there’s any slight change in diet, or the insulin intake. IN105, on the other hand, is a rapid acting drug and staves off the risk of hypoglycemia, argues Iyer.
Big Pharma, with its niche in the conventional small molecule drug, hasn’t fancied the biotechnology route for diabetes. The only oral insulin close to the market, according to Dr Misra, is a spray called Oralyn, developed by the Toronto, Canada-based Generex Biotechnology Corp., which has a marketing agreement for India with Shreya Life Sciences Pvt. Ltd, Mumbai.
...
Biocon Hold from BL
Posted by : sanecouncel.Tracked by: 1 Boarder
other reason is , many small investors fear to buy shares quoting above 200 and after bonus biocon price will came with in their sentimental range and they will start buying and share price cwill fall for sure...
In reply to:
Biocon Hold from BL
Posted by : sanecouncel.
very simple , you will get bonus as well as rax incentive if u dont sell in cash and you can buy when share fall.no mazor reason....
Biocon Hold from BL
Posted by : sanecouncel.Tracked by: 1 Boarder
very simple , you will get bonus as well as rax incentive if u dont sell in cash and you can buy when share fall.no mazor reason.......
In reply to:
Biocon Hold from BL
Posted by : psgs
why do you suggest selling in sept. series. will the stock gain in september? please give reasons and explain.
swamy.
No plans to exit from Biocon
Posted by : shenoyTracked by: 0 Boarder
Promoters of India\\`s leading drug firm Ranbaxy may consider consolidation as the name of the game in the pharmaceutical sector, but biotech major Biocon Chairman and Managing Director Kiran Mazumdar has ruled out selling off the company in her lifetime.
As a first generation entrepreneur, the emotional attachment to the company is very strong and I think in my lifetime I would like to grow this company myself, Biocon CMD Kiran Mazumdar Shaw told Sahara Samay Netowrk in an interview.
Her statement comes in the wake of Ranbaxy promoters selling off their entire stake for Rs 10,000 crore.
I think usually when you look at merger and acquisition, it is the next generation who are not so emotionally tied to the company that they look at it more pragmatically, a business kind of proposal, she said.
Speaking about the recent trend in the sector she said, There are lot of things happening in this particular area of mergers and acquisitions (M&A) and there are companies which have basically felt that may be in order to grow, may be an M&A approach is a much safer and better way of doing that.
She, however, said there were huge challenges and uncertainties, associated with risks ahead.
The whole sector is in the state of flux where you know people are risk averse, people want to find very instant solutions to these kinds of challenges, she added. ...
Biocon Hold from BL
Posted by : psgsTracked by: 1 Boarder
why do you suggest selling in sept. series. will the stock gain in september? please give reasons and explain.
swamy.
...
In reply to:
Biocon Hold from BL
Posted by : sanecouncel.
why you should sell in cash market on 19th. if you have 900 shares now sell 900 in future on 18th or any time in spt sereies
Biocon Hold from BL
Posted by : sanecouncel.Tracked by: 1 Boarder
why you should sell in cash market on 19th. if you have 900 shares now sell 900 in future on 18th or any time in spt sereies...
In reply to:
Biocon Hold from BL
Posted by : psgs
can i sell the original shares on 19th aug 2008 and still be eligible for bonus shares which will get credited by 25th or 26th of aug 2008.
swamy.
Biocon Hold from BL
Posted by : sanecouncel.Tracked by: 1 Boarder
we are not saying anything wrong.biocon bulls have no face to show .i really feel sad for those small investors put in money in 2004 and still waiting helplessly for ay return.only promise. who will buy syngene ipo by this kind of performence by parent company.savewrji has tried his best to defend this co but failed miserebly.am i correct saveraji?...
In reply to:
Biocon Hold from BL
Posted by : Guest
Very sad that now days biocon board become full of jok ers like Sane, Psgc trying bull ying innocent investors. They are trying to tr ap the investors so that they can exit from bio con.
Genuine boarders like Savera Patna is missing.
6 queries on Biocon
see moreMore from the Pharmaceuticals Sector
Boarders tracking Biocon
see more News Updates on Biocon
